Where does Cellivery Therapeutics, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Cellivery Therapeutics, Inc. ranks #19,584 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Cellivery Therapeutics, Inc. hold?

Cellivery Therapeutics, Inc. holds 14 US utility patents granted between 2019 and 2022, spanning 6 technology areas.

What is Cellivery Therapeutics, Inc.'s Innovation Score?

Cellivery Therapeutics, Inc. has an Innovation Score of 26.5 out of 100 (21st percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Cellivery Therapeutics, Inc. focus on?

Cellivery Therapeutics, Inc.'s top technology area is C07K (Peptides) with 14 patents, ranking #671 of 3,615 assignees active in that subclass. Grants appear in 6 CPC subclasses total.

Is Cellivery Therapeutics, Inc.'s patent grant rate increasing or decreasing?

Cellivery Therapeutics, Inc.'s recent grant velocity is +150% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Cellivery Therapeutics, Inc.'s patents?

Cellivery Therapeutics, Inc.'s patents average 12.4 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Cellivery Therapeutics, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Cellivery Therapeutics, Inc.

USPTO PatentsView assignee record - 14 granted patents across 6 technology areas, recorded in grant years 2019–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cellivery ranks #19,584 of 49,997 tracked US assignees by granted-patent volume, with 14 patents across 6 technology areas.

#19,584
of 49,997 US assignees by volume: 21st percentile
by Innovation Score (26.5/100): 12.4
avg claims per patent: +150%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R19584 · Foreign Corporation #19,584 · 14 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 14 grants
MID-PACK #19,584/49,997
PHOTO-FINISH Cecelumen
CPC-NARROW C07K · 6 areas
INNOV-THIN 26.5/100
CLAIMS-RICH 12.4 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +150% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cecelumen, LLC (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cellivery’s 26.5 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 9.4 pts (35%) Velocity 1.1 pts (4%) Breadth 8.7 pts (33%) Claim depth 7.4 pts (28%)

Qualcomm Incorporated · highest

85
Cellivery Therapeutics · this assignee

27
3D Lighting… · lowest

7

What this shows Cellivery's Innovation Score is 26.5/100 (21st percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cellivery?

Each dot is one of Cellivery’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cellivery’s own 12.4 claims/patent is ABOVE the 10.1 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Cellivery vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cellivery's grants concentrate

Cellivery Therapeutics, Inc. is a focused PatentsView assignee: 6 CPC subclasses with 100% of grants classified under C07K (Peptides). Peak complete grant year is 2020 (6 grants) versus a trough of 2 in 2021. By volume, Cellivery sits between Cecelumen, LLC and Certoplast Technische Klebebaender GMBH.

Cellivery's three-year grant acceleration

Cellivery Therapeutics, Inc. shows 2 grants in 2022–2024 against only 12 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cecelumen

14
Celagenex Researc…

14
Celerint

14
Cellcentric & KG

14
Cellresearch PTE

14
Cempra Pharmaceut…

14
Certis Cisco Secu…

14
Certoplast Techni…

14
Cellivery Therape… ◀

14

What this shows Cellivery holds 14 patents at rank #19,569, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Cellivery

By rank, the assignees closest to #19,569 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Cellivery's primary technology class.

Cellivery's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

27 21st percentile higher than 21% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

Cellivery Therapeutics, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	4	28.6%
2020	6	42.9%
2021	2	14.3%
2022	2	14.3%

Which technologies does Cellivery Therapeutics, Inc. patent most?

C07K - Peptides 14

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 9

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 4

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 3

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 3

C12Y - Enzymes 2

Top 6 of 6 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Cellivery Therapeutics, Inc.'s patent record in context - here's where to go next.

Cellivery Therapeutics, Inc.'s lead technology class is C07K (Peptides), 100% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #19,584 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Cellivery Therapeutics, Inc. against Cecelumen, LLC, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 26.5/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.